Myomo (MYO) 10-Q 3 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 01, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Trading Symbol	MYO
Entity Registrant Name	MYOMO, INC.
Entity Central Index Key	0001369290
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		7,000,169
Entity File Number	001-38109
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Tax Identification Number	47-0944526
Entity Address, Address Line One	137 Portland St.
Entity Address, Address Line Two	4th Floor
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02114
City Area Code	617
Local Phone Number	996-9058
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Security Exchange Name	NYSEAMER
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 10,235,914	$ 15,524,378
Accounts receivable, net	1,357,477	1,960,037
Inventories, net	1,260,936	808,308
Prepaid expenses and other current assets	451,100	799,164
Total Current Assets	13,305,427	19,091,887
Operating lease assets with right of use	695,933	632,906
Equipment, net	283,317	275,289
Investment in Jiangxi Myomo Medical Assistive Appliance Co. Ltd.	165,792	0
Other assets	111,034	95,330
Total Assets	14,561,503	20,095,412
Current Liabilities:
Accounts payable and accrued expenses	3,445,339	3,949,784
Current operating lease liability	436,694	333,380
Deferred revenue	2,211	249
Total Current Liabilities	3,884,244	4,283,413
Deferred revenue, net of current portion	934	1,246
Non-current operating lease liability	328,729	401,622
Total Liabilities	4,213,907	4,686,281
Commitments and Contingencies	0	0
Stockholders’ Equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock par value $0.0001 per share, 65,000,000 shares authorized; 6,879,904 and 6,869,753 shares issued as of March 31, 2022 and December 31, 2021, respectively; and 6,879,877 and 6,869,726 shares outstanding at March 31, 2022 and December 31, 2021, respectively	698	687
Additional paid-in capital	94,149,289	93,537,807
Accumulated other comprehensive loss	(9,849)	(60,677)
Accumulated deficit	(83,786,078)	(78,062,222)
Treasury stock, 27 shares at cost	(6,464)	(6,464)
Total Stockholders’ Equity	10,347,596	15,409,131
Total Liabilities and Stockholders’ Equity	$ 14,561,503	$ 20,095,412

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	65,000,000	65,000,000
Common stock, shares issued	6,977,062	6,869,753
Common stock, shares outstanding	6,977,035	6,869,726
Treasury shares at cost	27	27

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue	$ 3,677,575	$ 3,104,294	$ 7,545,501	$ 5,440,783
Cost of revenue	1,266,938	901,566	2,556,800	1,524,718
Gross profit	2,410,637	2,202,728	4,988,701	3,916,065
Operating expenses:
Research and development	632,872	600,116	1,292,408	1,126,083
Selling, general and administrative	4,664,088	4,202,244	9,320,505	8,322,047
Total operating expenses	5,296,960	4,802,360	10,612,913	9,448,130
Loss from operations	(2,886,323)	(2,599,632)	(5,624,212)	(5,532,065)
Other (income) expense
Other (income) expense, including interest income, net	(4,174)	6,018	(3,384)	6,137
Loss on investment in minority interest	33,208		33,208
Total other expense (income)	29,034	6,018	29,824	6,137
Loss before income taxes	(2,915,357)	(2,605,650)	(5,654,036)	(5,538,202)
Income tax expense	(6,435)	15,665	69,820	43,907
Net loss	$ (2,908,922)	$ (2,621,315)	$ (5,723,856)	$ (5,582,109)
Weighted average number of common shares outstanding:
Basic and diluted	6,923,799	5,639,524	6,904,966	5,416,708
Basic and diluted	6,923,799	5,639,524	6,904,966	5,416,708
Net loss per share attributable to common stockholders
Basic and diluted	$ (0.42)	$ (0.46)	$ (0.83)	$ (1.03)
Basic and diluted	$ (0.42)	$ (0.46)	$ (0.83)	$ (1.03)
Product Revenue
Revenue	$ 3,677,575	$ 3,104,294	$ 6,545,501	$ 5,440,783
License Revenue
Revenue	$ 0		$ 1,000,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (2,908,922)	$ (2,621,315)	$ (5,723,856)	$ (5,582,109)
Other comprehensive income, net of tax:
Foreign currency translation gain	41,583	2,413	50,828	10,466
Other comprehensive income	41,583	2,413	50,828	10,466
Comprehensive loss	$ (2,867,339)	$ (2,618,902)	$ (5,673,028)	$ (5,571,643)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Total	Common Stock	Additional Paid-in Capital [Member]	Comprehensive Loss [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
Beginning balance at Dec. 31, 2020	$ 11,565,374	$ 457	$ 79,273,964	$ 12,690	$ 67,689,893	$ 6,464
Beginning balance, shares at Dec. 31, 2020		4,593,184				27
Exercise of warrants	7,288,275	$ 102	7,288,173
Exercise of warrants, shares		999,445
Common stock issued upon vesting of restricted stock units		$ 1	1
Common stock issued upon vesting of restricted stock units, Shares		11,397
Restricted stock vested, shares		10
Stock-based compensation	165,971		165,971
Unrealized gain on foreign currency	8,323			8,323
Net loss	(2,960,794)				(2,960,794)
Ending balance at Mar. 31, 2021	16,067,149	$ 560	86,728,107	(4,367)	(70,650,687)	$ (6,464)
Ending balance, shares at Mar. 31, 2021		5,604,036				27
Beginning balance at Dec. 31, 2020	11,565,374	$ 457	79,273,964	12,690	67,689,893	$ 6,464
Beginning balance, shares at Dec. 31, 2020		4,593,184				27
Net loss	(5,582,109)
Ending balance at Jun. 30, 2021	13,811,289	$ 570	87,091,409	(2,224)	73,272,002	$ 6,464
Ending balance, shares at Jun. 30, 2021		5,700,895				27
Beginning balance at Mar. 31, 2021	16,067,149	$ 560	86,728,107	(4,367)	(70,650,687)	$ (6,464)
Beginning balance, shares at Mar. 31, 2021		5,604,036				27
Common stock issued upon vesting of restricted stock units		$ 10	(10)
Common stock issued upon vesting of restricted stock units, Shares		96,849
Restricted stock vested, shares		10
Stock-based compensation	363,312		363,312
Unrealized gain on foreign currency	2,143			2,143
Net loss	(2,621,315)				(2,621,315)
Ending balance at Jun. 30, 2021	13,811,289	$ 570	87,091,409	(2,224)	73,272,002	$ 6,464
Ending balance, shares at Jun. 30, 2021		5,700,895				27
Beginning balance at Dec. 31, 2021	15,409,131	$ 687	93,537,807	(60,677)	78,062,222	$ (6,464)
Beginning balance, shares at Dec. 31, 2021		6,869,753				27
Common stock issued upon vesting of restricted stock units		$ 1	(1)
Common stock issued upon vesting of restricted stock units, Shares		10,151
Stock-based compensation	266,270		266,270
Unrealized gain on foreign currency	9,245			9,245
Net loss	(2,814,934)				2,814,934
Ending balance at Mar. 31, 2022	12,869,712	$ 688	93,804,076	(51,432)	80,877,156	$ (6,464)
Ending balance, shares at Mar. 31, 2022		6,879,904				27
Beginning balance at Dec. 31, 2021	15,409,131	$ 687	93,537,807	(60,677)	78,062,222	$ (6,464)
Beginning balance, shares at Dec. 31, 2021		6,869,753				27
Net loss	(5,723,856)
Ending balance at Jun. 30, 2022	10,347,596	$ 698	94,149,289	(9,849)	(83,786,078)	$ (6,464)
Ending balance, shares at Jun. 30, 2022		6,977,062				27
Beginning balance at Mar. 31, 2022	12,869,712	$ 688	93,804,076	(51,432)	80,877,156	$ (6,464)
Beginning balance, shares at Mar. 31, 2022		6,879,904				27
Common stock issued upon vesting of restricted stock units		$ 10	(10)
Common stock issued upon vesting of restricted stock units, Shares		97,158
Stock-based compensation	345,223		345,223
Unrealized gain on foreign currency	41,583			41,583
Net loss	(2,908,922)				(2,908,922)
Ending balance at Jun. 30, 2022	$ 10,347,596	$ 698	$ 94,149,289	$ (9,849)	$ (83,786,078)	$ (6,464)
Ending balance, shares at Jun. 30, 2022		6,977,062				27

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (5,723,856)	$ (5,582,109)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation	94,645	58,329
Stock-based compensation	611,493	529,283
Bad debt expense	26,075	0
Loss on disposal of asset	0	202
Amortization of right-of-use assets	162,638	66,653
Loss on equity investment	33,208	0
Other non-cash charges	69,521	1,772
Changes in operating assets and liabilities:
Accounts receivable	602,033	(194,455)
Inventories	(496,529)	(28,200)
Prepaid expenses and other current assets	345,470	(426,749)
Other assets	(15,704)	0
Accounts payable and accrued expenses	(485,997)	17,926
Operating Lease Liabilities	(195,244)	54,983
Deferred revenue	1,650	(2,512)
Other liabilities	0	(4,637)
Net cash used in operating activities	(4,970,597)	(5,509,514)
CASH FLOWS FROM INVESTING ACTIVITIES
Investment in Jiangxi Myomo Medical Assistive Appliance Co. Ltd.	(199,000)	0
Purchases of equipment	(102,672)	(247,644)
Net cash used in investing activities	(301,672)	(247,644)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of warrants	0	7,288,275
Proceeds from payments under grants	0	1,208
Net cash provided by financing activities	0	7,289,483
Effect of foreign exchange rate changes on cash	(16,195)	(1,122)
Net (decrease) increase in cash, cash equivalents and restricted cash	(5,288,464)	1,531,203
Cash, cash equivalents and restricted cash, beginning of period	15,524,378	12,241,261
Cash, cash equivalents and restricted cash, end of period	10,235,914	13,772,464
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Right of use assets obtained in exchange for lease liabilities	225,665	654,091
Property and equipment included in accounts payable and in accrued expenses and other liabilities	$ 0	$ 36,102

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1 — Description of Business Myomo Inc. (“Myomo” or the Company”) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro ® myoelectric upper limb orthosis product is registered with the U.S. Food and Drug Administration as a Class II medical device. The Company sells its products directly to patients, to orthotics and prosthetics (O&P) providers around the world, the Veterans Health Administration, and distributors in Europe and Australia. The Company was incorporated in the State of Delaware on September 1, 2004 and is headquartered in Boston, Massachusetts. Liquidity The Company incurred net losses of approximately $ 5.7 million and $ 5.6 million during the six months ended June 30, 2022 and 2021, respectively, and has an accumulated deficit of approximately $ 83.8 million and $ 78.1 million at June 30, 2022 and December 31, 2021, respectively. Cash used in operating activities was approximately $ 5.0 million and $ 5.5 million for the six months ended June 30, 2022 and 2021, respectively. The Company has historically funded its operations through financing activities, including raising equity and debt capital. The Company’s operating plans are primarily focused on scaling up its operations, increasing the proportion of patients carrying commercial insurance with payers that have historically reimbursed for the Company’s products and continued work with the Centers for Medicare and Medicaid Services, or CMS, and their administrative contractors regarding reimbursement of its products. In addition, the Company believes that it has access to capital resources through payment of the remaining license fee associated with the Company’s entry into a joint venture and technology license agreement with Beijing Ryzur Medical Investment Co., Ltd. On August 2, 2022, the Company entered into a Common Stock Purchase Agreement ("Purchase Agreement") with Keystone Capital Partners ("Keystone"), under which the Company at its sole discretion can direct Keystone to purchase the Company's common stock at a discount to the then current market price. Keystone is committed to purchase a minimum of 1,399,348 shares, which represents a value of approximately $ 2.3 million as of August 2, 2022, after application of the discount market price and a maximum of $ 5.0 million under the twenty-four (24) month term of the Purchase Agreement. See Note 10 - Subsequent Events, for further discussion. The Company may also undertake public or private equity offerings, obtain proceeds from exercises of outstanding warrants, debt financings, or other means. Debt financing may require the Company to pledge assets and enter into covenants that could restrict certain business activities or its ability to incur further indebtedness; and may contain other terms that are not favorable to the Company or its stockholders. Based on the Company’s cash balance of approximately $ 10.2 million as of June 30, 2022 , committed capital from its Purchase Agreement with Keystone and its expected cash flows, the Company believes that its available cash plus committed capital will be sufficient to fund its operations for at least the next 12 months from issuance date of these financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Interim Financial Statements The accompanying unaudited condensed consolidated financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These statements have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) that are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of June 30, 2022 and for the three and six months ended June 30, 2022. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the operating results for the fiscal year ending December 31, 2022, or any other period. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2021 and 2020 and for the years then ended, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 . Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary Myomo Europe GmbH. All significant intercompany balances and transactions are eliminated. Reclassifications Certain prior year amounts in prepaid expenses and other current assets have been reclassified to other assets to conform with the current year presentation. Comprehensive Loss Comprehensive loss inclu des all changes in equity during a period, except those resulting from investments by stockholders and distributions to stockholders. The Company's comprehensive loss includes changes in foreign currency translation adjustments. There were no reclassifications out of accumulated other comprehensive loss in the three and six months ended June 30, 2022, and 2021, respectively. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from these estimates. The Company’s significant estimates include the allowance for doubtful accounts, deferred tax valuation allowances, valuation of stock-based compensation, warranty obligations and reserves for slow-moving inventory. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less from purchase date to be cash equivalents. Cash and cash equivalents consist principally of deposit accounts and money market accounts at June 30, 2022 and December 31, 2021 . Accounts Receivable and Allowance for Doubtful Accounts The Company reports accounts receivable at invoiced amounts less an allowance for doubtful accounts. The Company evaluates its accounts receivable on a continuous basis, and if necessary, establishes an allowance for doubtful accounts based on a number of factors, including current credit conditions and customer payment history. The Company does not require collateral or accrue interest on accounts receivable and credit terms are generally 30 days. At June 30, 2022 , the Company recorded an allowance for doubtful accounts of approximately $ 26,000 . There was no allowance for doubtful accounts as of December 31, 2021 . Joint Venture On March 28, 2022, the Company invested cash consideration of $ 199,000 for a 19.9 % ownership stake in Jiangxi Myomo Medical Assistive Appliance Co., Ltd. (the “JV”), a company headquartered in China that is majority-owned by Beijing Ryzur Medical Investment Co., Ltd. (“Ryzur Medical”). The JV will manufacture and sell the Company’s current and future products in greater China, including Hong Kong, Macau and Taiwan. The Company accounts for its investment in the JV under the equity method because the Company exerts significant influence over its management. The investment is included in total assets on the condensed consolidated balance sheet . There was no impairment charge for t he three months ended June 30, 2022 , associated with this equity investment. The Company records its share of the JV’s earnings in its condensed consolidated statement of operations in other expense (income). The Company recorded a loss on investment in minority interest of $ 33,208 for the three and six months ended of June 30, 2022 . Revenue Recognition Revenues under ASC 606 and related amendments (Topic 606) are required to be recognized either at a “point in time” or “over time,” depending on the facts and circumstances of the arrangement, and are evaluated using a five-step model. The Company recognizes revenue after applying the following five steps: 1) Identification of the contract, or contracts, with a customer, 2) Identification of the performance obligations in the contract, including whether they are distinct within the context of the contract 3) Determination of the transaction price, including the constraint on variable consideration 4) Allocation of the transaction price to the performance obligations in the contract 5) Recognition of revenue when, or as, performance obligations are satisfied Revenue is recognized when control of these services is transferred to our customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. Product Revenue Increasingly, the Company derives its revenue from direct billing. The Company also derives revenue from the sale of its products to O&P providers in the United States and internationally, the Veterans Administration (“VA”) and distributors in Europe and Australia. Under direct billing, the Company recognizes revenue when all of the following criteria are met: (i) The product has been delivered to the patient, including completion of initial instruction on its use. (ii) Collection is deemed probable and it has been determined that a significant reversal of the revenue to be recognized is not deemed probable when the uncertainty associated with the variable consideration is resolved. As an example, the Company will record revenue if it is notified that insurance intends to pay and a payment amount is provided. (iii) The amount to be collected is estimable using the “expected value” estimation techniques, or the “most likely amount” as defined in ASC 606. For revenue derived from certain insurance companies where the Company has demonstrated sufficient payment history, the Company recognizes revenue when it receives a pre-authorization from the insurance company and control passes to the patient upon delivery of the device in an amount the reflects the consideration the Company expects to receive in exchange for the device. During the fourth quarter of 2020, the Company made such a determination for certain insurers. These insurers represent ed 34 % and 40 % of direct billing channel revenue during the three months ended June 30, 2022 and June 30, 2021 , respectively. These insurers represented 41 % and 28 % o f direct billing channel revenue during six months ended June 30, 2022 and June 30, 2021, respectively. Depending on the timing of product deliveries to customers, which is when cost of revenue must be recorded, and when the Company meets the criteria to record revenue, there may be fluctuations in gross margin. During the three months ended June 30, 2022 and 2021, the Company recognized revenue of approximate ly $ 1,651,900 and $ 397,100 , respectively, and during the six months ended June 30, 2022 and 2021, the Company recognized revenue of approximate ly $ 1,284,200 a nd $ 1,489,700 , respectively, from O&P providers or third-party payers for which costs related to the completion of the Company’s performance obligations were recorded in a prior period. For revenues derived from O&P providers, the VA and rehabilitation hospitals, the Company recognizes revenue when control passes to the customer in an amount that reflects the consideration the Company expects to receive in exchange for those services. Revenues may be recognized upon shipment or upon delivery, depending on the terms of the arrangement, provided that persuasive evidence of an arrangement exists, there are no uncertainties regarding customer acceptance and collectability is deemed probable. In certain cases, the Company ships its products to O&P providers pending reimbursement from non-government, third party payers. As a result of this arrangement, elements of the revenue recognition criteria have not been met upon shipment. In this instance, the Company recognizes revenue when the amount is estimable and the Company determines it is probable that payment will be received. In many cases, the Company is not able to recognize revenue in these situations until payment is received, as then all of the revenue recognition criteria have been met. The Company has elected to record taxes collected from customers on a net basis and does not include tax amounts in revenue or cost of revenue. License Revenue If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when the license is transferred to the customer, the customer is able to use and benefit from the license, and collectability is deemed probable. On January 21, 2021, we entered into a definitive agreement with Beijing Ryzur Medical Investment Co., Ltd. (“Ryzur Medical”), a medical device manufacturer based in Beijing, to form a joint venture (the “JV”) to manufacture and sell our current and future products in greater China, including Hong Kong, Macau and Taiwan (the “JV Agreement”). Under the Agreements, we are entitled to receive an upfront license fee of $ 2.7 million, of which $ 1.0 million has been paid and recognized as revenue as of June 30, 2022. The company will recognize revenue on the remaining amount due upon payment as the fee has not been paid according the to the contractual terms. Contract Balances The timing of revenue recognition may differ from the timing of payment by customers. The Company records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. The Company had approximately $ 3,100 and $ 1,500 of deferred revenue as of June 30, 2022 and December 31, 2021, respectively. Disaggregated Revenue from Contracts with Customers The following table presents revenue by major source: For the Three Months For the Six Months 2022 2021 2022 2021 Direct to patient $ 3,056,588 $ 2,300,129 $ 4,908,732 $ 4,027,059 Clinical/Medical providers 620,987 804,165 $ 1,636,769 $ 1,413,724 License revenue - - 1,000,000 - Total revenue from contracts with customer $ 3,677,575 $ 3,104,294 $ 7,545,501 $ 5,440,783 Geographic Data The Company generated 91 % of its total and product revenue from the United States, 9 % from Germany, and an immaterial amount from other international locations for the three months ended June 30, 2022. The Company generated 90 % of its product and total revenue from the United States, 10 % from Germany, and immaterial amounts from international locations for the three months ended June 30, 2021. During the six months ended June 30, 2022, the Company generated 74 % of its total revenues from the United States, 12 % from Germany, 13 % from China and 1 % from other international locations. Excluding license revenue during the six months ended June 30, 2022, the Company generated 85 % of its product revenues from the United States, 14 % from Germany and 1 % from other international locations. During the six months ended June 30, 2021, the Company generated 89 % of its total and product revenues from the United States, 11 % from Germany, and immaterial amounts from other international locations Cost of Revenue In conjunction with the adoption of ASC 606, there are certain cases in which the Company will expense costs when incurred as required by ASC 340-40-25. In certain cases, the Company ships the MyoPro device to O&P providers, or provides the device directly to patients, pending reimbursement from third-party payers, after which revenue is recognized. For the three and six months ended June 30, 2022 , the Company recorded cost of goods sold of approximately $ 254,900 and $ 395,400 , resp ectively without corresponding revenue, respectively. For the three and six months ended June 30, 2021, the Company recorded cost of goods sold of $ 69,900 and $ 94,700 witho ut corresponding revenue, respectively. Direct billing fees paid to O&P providers for services they provide in conjunction with patient evaluations are expensed as incurred as required by ASC 340-40-25, as a cost of obtaining a contract. These costs are recorded as sales and marketing expense. Internal costs incurred and fees paid to O&P providers to measure, fit and deliver the device to patients are expensed to cost of revenue. Advertising The Company charges the costs of advertising to operating expenses as incurred. Advertising expense amounted to approximately $ 1,036,200 and $ 766,500 during the three months ended June 30, 2022 and 2021 , respectively and approximately $ 1,989,600 and $ 1,609,100 during the six months ended June 30, 2022 and 2021 , respectively. Foreign Currency Translation The functional currency of the Company’s foreign subsidiary, Myomo Europe GmbH, is the Euro. Net foreign currency gains and losses during the three and six months ended June 30, 2022 were immaterial and included in accumulated other comprehensive loss in the condensed consolidated balance sheet. Transaction foreign exchange gains and losses are included in net loss. Foreign exchange translation gains and losses from the functional currency of Myomo Europe GmbH, which is the Euro, to U.S. dollars are captured in other comprehensive loss. The balance sheet is translated using the spot rate on the day of reporting and the income statement is translated monthly using the average rate for the month. Net Loss per Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding, plus potentially dilutive common shares. Restricted stock, restricted stock units, stock options and warrants are excluded from the diluted net loss per share calculation when their impact is antidilutive. The Company reported a net loss for the three and six months ended June 30, 2022 and 2021, and as a result, all potentially dilutive common shares are considered antidilutive for these periods. Potential common shares issuable consist of the following at: June 30, 2022 2021 Stock options 31,390 29,326 Restricted stock units 513,631 299,484 Restricted stock - 10 Warrants 691,554 1,709,441 Total 1,236,575 2,038,261 Recent Accounting Standards In May 2021, the FASB issued ASU 2021-04 Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early application is permitted, including in an interim period as of the beginning of the fiscal year that includes that interim period. We adopted the provisions of ASU 2021-04 in the fourth quarter of 2021. The implementation resulted in a deemed dividend of approximately $ 640,000 on the discounting and repricing of certain warrants. Subsequent Events The Company evaluates whether there have been subsequent events through the date the financial statements were issued and determines whether subsequent events exist that would require recognition in the financial statements or disclosure in the notes to the financial statements.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Inventories	Note 3 — Inventories Inventories consist of the following at: June 30, December 31, Finished goods $ 453,840 $ 176,082 Work in process 18,684 23,161 Rental units 62,531 62,531 Parts and subassemblies 772,457 584,996 1,307,512 846,770 Less: reserve for rental units ( 46,576 ) ( 38,462 ) Inventories, net $ 1,260,936 $ 808,308

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 4 — Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”), which defines fair value, establishes a framework for measuring fair value, and establishes disclosures about fair value measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: • Level 1 — Quoted prices available in active markets for identical assets or liabilities. • Level 2 — Observable inputs other than quoted prices included in Level 1, such as quotable prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs. The carrying amounts of the Company’s financial instruments such as cash and cash equivalents, restricted cash, accounts receivable and accounts payable, approximate fair value due to the short-term nature of these instruments. Cash equivalents are a money market fund that limits its investments to only short-term U.S. Treasury securities and repurchase agreements related to these securities. Cash equivalents measured at fair value on a recurring basis at June 30, 2022 were as follows: In Active Significant Significant Total Cash equivalents $ 9,205,167 $ — $ — $ 9,205,167 Cash equivalents measured at fair value on a recurring basis at December 31, 2021 were as follows: In Active Markets for Identical Assets or Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Cash equivalents $ 14,803,456 $ — $ — $ 14,803,456

Accounts Payable and other Accr

Accounts Payable and other Accrued Expenses	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Accounts Payable and other Accrued Expenses	Note 5 - Accounts payable and accrued expenses: Accounts Payable and Other Accrued Expenses consists of the following at: June 30, December 31, Trade payables $ 859,536 $ 723,352 Accrued compensation and benefits 1,115,643 2,188,869 Accrued professional services 110,706 108,417 Deferred payroll taxes under CARES Act 113,423 113,423 Warranty reserve 200,465 176,281 Customer Deposits 659,059 192,501 Other 386,507 446,941 $ 3,445,339 $ 3,949,784

Common Stock and Warrants

Common Stock and Warrants	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Common Stock and Warrants	Note 6 — Common Stock and Warrants On February 13, 2020, the Company completed an underwritten public offering (the “ February 2020 Offering”). As part of the February 2020 offering, investors received 2,143,000 warrants (“Investor Warrants”), each entitling the holder to purchase one share of the Company’s common stock at an exercise price of $ 7.50 per share. The Investor Warrants expire on February 13, 2025 . In addition, the Company issued to the underwriters, warrants (the “Underwriter Warrants”) to purchase 230,373 shares of common stock. The Underwriter Warrants have an exercise price $ 7.00 per share. The Underwriter Warrants expire on February 13, 2025 . The Investor Warrants and Underwriter Warrants (collectively, the “Warrants”) are being accounted for as equity. There were no exercises of Warrants during the six months ended June 30, 2022. During the six months ended June 30, 2021, 826,700 Investor Warrants and 162,575 Underwriter Warrants were exercised. Proceeds received from the exercise of warrants was approximately $ 7,288,300 during the six months ended June 30, 2021. On June 25, 2021, the Company terminated its ATM facility with B. Riley FBR and entered into a new facility with Alliance Global Partners (“AGP”). The Company may offer and sell from time to time up to $ 15 million in shares of the Company’s common stock. The ATM facility with AGP has substantially the same terms as its prior facility with B. Riley FBR, including a commission payable in the amount of 3.0 % of the gross proceeds from the sales of common s tock. In conjunction with the execution of the Purchase Agreement with Keystone on August 2, 2022, the Company reduced the value of common stock it is entitled to sell under the ATM to $ 0.3 million as required under General Instruction I.B.6 of Form S-3. There were no sales under the ATM facility during the three and six months ended June 30, 2022. No shares of restricted stock vested during the three and six months ended June 30, 2022. During the three and six months ended June 30, 2021 , 10 and 20 shares of restricted stock vested, respectively

Stock Award Plans and Stock-bas

Stock Award Plans and Stock-based Compensation	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock Award Plans and Stock-based Compensation	Note 7 — Stock Award Plans and Stock-based Compensation Stock Option Awards The Company uses the Black-Scholes option pricing model to estimate the grant date fair value of its stock options. There was no income tax benefit recognized in the financial statements for share-based compensation arrangements for the three and six months ended June 30, 2022 and 2021. There were no stock options granted during the three months ended June 30, 2022 and 1,700 stock options granted during the six months ended June 30, 2022. The assumptions underlying the calculation of grant date fair value per share for the six months ended June 30, 2022 are as follows: For the Six Months 2022 Number of options granted 1,700 Weighted-average expected volatility 117.18 % Weighted-average risk-free interest rate 1.68 % Weighted-average expected option term 6.25 Weighted-average dividend yield — % Weighted-average fair value per share $ 6.92 The stock price volatility for the Company’s options was determined using the Company’s historical volatility. The risk-free interest rate was derived from U.S. Treasury rates existing on the date of grant for the applicable expected option term. The expected term represents the period of time that options are expected to be outstanding. Because the Company has only very limited historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period. The expected dividend yield assumption is based on the fact that the Company has never paid, nor has any intention to pay, cash dividends. As of June 30, 2022 , there were 38,209 shares available for issuance under the Myomo, Inc. 2018 Stock Option and Incentive Plan (the “2018 Plan”). On January 1, 2022, the number of shares reserved and available for issuance under the 2018 Plan increased by 274,789 shares pursuant to a provision in the 2018 Plan that provides that the number of shares of common stock reserved and available for issuance under the 2018 Plan will be cumulatively increased each January 1 by 4 % of the number shares of common stock outstanding on the immediately preceding December 31 or such lesser number of shares of common stock determined by management in consultation with members of the Board of Directors, including the compensation committee. Awards of restricted stock units may be net share settled upon vesting to cover the required employee statutory withholding taxes and the remaining amount is converted into shares based upon their share-value on the date the award vests. These payments of employee withholding taxes are presented in the statements of cash flows as a financing activity. Share-Based Compensation Expense The Company accounts for stock awards to employees and non-employees based upon the fair value of the award on the date of grant. The fair value of that award is then ratably recognized as expense over the period during which the recipient is required to provide services in exchange for that award. The Company attributes the value of stock-based compensation to operations on the straight-line method such that the expense associated with awards is evenly recognized over the vesting period. The Company recognized stock-based compensation expense related to the issuance of stock option awards, restricted stock awards and restricted stock units to employees, non-employees and directors in the statements of operations as follows: Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Cost of goods sold $ 23,184 $ 12,831 $ 24,354 $ 21,864 Research and development 29,573 24,707 76,107 72,110 Selling, general and administrative 292,466 325,774 511,032 435,309 Total $ 345,223 $ 363,312 $ 611,493 $ 529,283 As of June 30, 2022 , there was approximately $ 93,700 of unrecognized compensation cost related to unvested stock options that is expected to be recognized over a weighted-average period of 2.58 years. As of June 30, 2022 , there was approximately $ 2,057,300 of unrecognized compensation expense related to unvested restricted stock units that is expected to be recognized over a weighted-average period of 1.90 years.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 8 — Related Party Transactions The Company sold its products to an orthotics and prosthetics practice whose ownership includes an individual who is both a shareholder and executive officer of the Company. The executive resigned his position with the Company effective March 31, 2021. As a result, the orthotics and prosthetics practice is no longer a related party effective April 1, 2021. Sales to this related party were sold at standard list prices. During the six months ended June 30, 2021, approximately $ 25,900 of revenues were recognized from this previously related party. The Company also obtained consulting and fabrication services, reported in cost of goods sold, from the same previously related party. Charges for these services amounted to approximately $ 112,900 during the six months ended June 30, 2021.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 — Commitments and Contingencies Litigation We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened litigation against us that could have a material adverse effect on our business, operating results or financial condition. Operating Leases The Company has a non-cancelable sublease agreement for its corporate headquarters in Boston, MA expiring in 2023, and it has a non-cancelable lease agreement for its manufacturing space in Boston and office space in Fort Worth, TX both expiring in 2025 with early termination available at the company’s discretion in 2023. Termination options were not included in the lease term for the Company’s existing operating leases. Certain arrangements have discounted rent periods or escalating rent payment provisions. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheets. We recognize rent expense on a straight-line basis over the lease term. As of June 30, 2022, operating lease assets were $ 695,933 . The amount and the maturity of the Company’s operating lease liabilities as of June 30, 2022, are as follows: June 30, 2022 2022 (June 30 - December 31) $ 275,625 2023 411,142 2034 159,872 2025 67,981 2026 — Thereafter — Total future minimum lease payments 914,620 Less imputed interest 149,197 Total operating lease liabilities $ 765,423 Included in the condensed consolidated balance sheet: Current operating lease liabilities $ 436,694 Non-current operating lease liabilities 328,729 Total operating lease liabilities $ 765,423 For the three and six months ended June 30, 2022 and 2021, the total lease cost is comprised of the following amounts: For the Three Months For the Six Months 2022 2021 2022 2021 Operating lease expense 125,293 102,963 241,904 170,472 Short-term lease expense 1,300 2,175 3,250 25,859 Total lease expense $ 126,593 $ 105,138 $ 245,154 $ 196,331 The following summarizes additional information related to operating leases: June 30, 2022 Weighted-average remaining lease term (in years) 2.1 Weighted-average discount rate 20 % Major Customers For the three and six months ended June 30, 2022 and 2021, t here were no customers which accounted for more than 10% of product revenues. For the three and six months ended June 30, 2022 a U.S. insurance payer represented 28 % and 31 % of product reve nues, respectively. For the three and six months ended June 30, 2021 a U.S. insurance payer represented 30 % and 28 % of product reve nues, respectively. At both June 30, 2022 and 2021, one insurance company and its affiliates accounted for approximately 68 % of accounts receivable, respectively. For the three and six months ended June 30, 2022 , approximately 71 % and 63 % of the Company's product revenues, respectively, were derived from patients with Medicare Advantage insurance plans. For the three and six months ended June 30, 2021 , approximately 52 % and 54 % of the Company’s product revenues were derived from patients with Medicare Advantage insurance plans, respectively.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 10 — Subsequent Events O n August 2, 2022, ("the "Agreement Date"") the Company entered into a Purchase Agreement with Keystone, establishing an equity line facility under which the Company, at its sole discretion, can direct Keystone to purchase the Company's common stock from time to time through delivery of a purchase notice ("Notice"). The purchase price is at the lesser of prevailing market prices of the Company’s common stock as defined in the Purchase Agreement, at a 10 % discount. The aggregate size of the facility is $ 5 million (the “Maximum Amount”), provided that the Company has agreed to issue no more than 1,399,348 shares of common stock (the "Minimum Shares"), representing 19.99 % of the Company's outstanding shares on the Agreement Date, if the shareholder approval rules of the NYSE American apply and impose such a limit on this facility, which represents a value $ 2.3 million based on the closing price of the Company’s common stock on August 2, 2022 after application of the 10 % discount. During the twenty-four (2 4) month term of the Purchase Agreement, Keystone can purchase in excess of the Minimum Shares up to the Maximum Amount so long as the price per share paid by Keystone for an applicable purchase is in excess of the greater of the closing price of the Company's common stock or book value per share on the trading day immediately prior to the date of the purchase notice. Keystone's obligation to purchase shares of the Company's common stock is subject to the Company's ability to maintain an effective registration statement, continued listing on the NYSE American or other trading market and a minimum price per share of $ 0.50 , among other conditions. Keystone shall maintain a beneficial ownership limitation of 4.99 % of the Company's outstanding common stock during the Term. On the Agreement Date, the Company issued 50,000 shares to Keystone as a commitment fee and paid Keystone $ 20,000 for its expenses incurred in conjunction with the transaction. The Company evaluated subsequent events through the date the financial statements were issued, and determined that, except as disclosed herein, there have been no other subsequent events that would require recognition in the financial statements or disclosure in the notes to the financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Interim Financial Statements	Interim Financial Statements The accompanying unaudited condensed consolidated financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These statements have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) that are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of June 30, 2022 and for the three and six months ended June 30, 2022. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the operating results for the fiscal year ending December 31, 2022, or any other period. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2021 and 2020 and for the years then ended, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 .
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary Myomo Europe GmbH. All significant intercompany balances and transactions are eliminated.
Reclassifications	Reclassifications Certain prior year amounts in prepaid expenses and other current assets have been reclassified to other assets to conform with the current year presentation.
Comprehensive Loss	Comprehensive Loss Comprehensive loss inclu des all changes in equity during a period, except those resulting from investments by stockholders and distributions to stockholders. The Company's comprehensive loss includes changes in foreign currency translation adjustments. There were no reclassifications out of accumulated other comprehensive loss in the three and six months ended June 30, 2022, and 2021, respectively.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from these estimates. The Company’s significant estimates include the allowance for doubtful accounts, deferred tax valuation allowances, valuation of stock-based compensation, warranty obligations and reserves for slow-moving inventory.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less from purchase date to be cash equivalents. Cash and cash equivalents consist principally of deposit accounts and money market accounts at June 30, 2022 and December 31, 2021 .
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts The Company reports accounts receivable at invoiced amounts less an allowance for doubtful accounts. The Company evaluates its accounts receivable on a continuous basis, and if necessary, establishes an allowance for doubtful accounts based on a number of factors, including current credit conditions and customer payment history. The Company does not require collateral or accrue interest on accounts receivable and credit terms are generally 30 days. At June 30, 2022 , the Company recorded an allowance for doubtful accounts of approximately $ 26,000 . There was no allowance for doubtful accounts as of December 31, 2021 .
Joint Venture	Joint Venture On March 28, 2022, the Company invested cash consideration of $ 199,000 for a 19.9 % ownership stake in Jiangxi Myomo Medical Assistive Appliance Co., Ltd. (the “JV”), a company headquartered in China that is majority-owned by Beijing Ryzur Medical Investment Co., Ltd. (“Ryzur Medical”). The JV will manufacture and sell the Company’s current and future products in greater China, including Hong Kong, Macau and Taiwan. The Company accounts for its investment in the JV under the equity method because the Company exerts significant influence over its management. The investment is included in total assets on the condensed consolidated balance sheet . There was no impairment charge for t he three months ended June 30, 2022 , associated with this equity investment. The Company records its share of the JV’s earnings in its condensed consolidated statement of operations in other expense (income). The Company recorded a loss on investment in minority interest of $ 33,208 for the three and six months ended of June 30, 2022 .
Revenue Recognition	Revenue Recognition Revenues under ASC 606 and related amendments (Topic 606) are required to be recognized either at a “point in time” or “over time,” depending on the facts and circumstances of the arrangement, and are evaluated using a five-step model. The Company recognizes revenue after applying the following five steps: 1) Identification of the contract, or contracts, with a customer, 2) Identification of the performance obligations in the contract, including whether they are distinct within the context of the contract 3) Determination of the transaction price, including the constraint on variable consideration 4) Allocation of the transaction price to the performance obligations in the contract 5) Recognition of revenue when, or as, performance obligations are satisfied Revenue is recognized when control of these services is transferred to our customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. Product Revenue Increasingly, the Company derives its revenue from direct billing. The Company also derives revenue from the sale of its products to O&P providers in the United States and internationally, the Veterans Administration (“VA”) and distributors in Europe and Australia. Under direct billing, the Company recognizes revenue when all of the following criteria are met: (i) The product has been delivered to the patient, including completion of initial instruction on its use. (ii) Collection is deemed probable and it has been determined that a significant reversal of the revenue to be recognized is not deemed probable when the uncertainty associated with the variable consideration is resolved. As an example, the Company will record revenue if it is notified that insurance intends to pay and a payment amount is provided. (iii) The amount to be collected is estimable using the “expected value” estimation techniques, or the “most likely amount” as defined in ASC 606. For revenue derived from certain insurance companies where the Company has demonstrated sufficient payment history, the Company recognizes revenue when it receives a pre-authorization from the insurance company and control passes to the patient upon delivery of the device in an amount the reflects the consideration the Company expects to receive in exchange for the device. During the fourth quarter of 2020, the Company made such a determination for certain insurers. These insurers represent ed 34 % and 40 % of direct billing channel revenue during the three months ended June 30, 2022 and June 30, 2021 , respectively. These insurers represented 41 % and 28 % o f direct billing channel revenue during six months ended June 30, 2022 and June 30, 2021, respectively. Depending on the timing of product deliveries to customers, which is when cost of revenue must be recorded, and when the Company meets the criteria to record revenue, there may be fluctuations in gross margin. During the three months ended June 30, 2022 and 2021, the Company recognized revenue of approximate ly $ 1,651,900 and $ 397,100 , respectively, and during the six months ended June 30, 2022 and 2021, the Company recognized revenue of approximate ly $ 1,284,200 a nd $ 1,489,700 , respectively, from O&P providers or third-party payers for which costs related to the completion of the Company’s performance obligations were recorded in a prior period. For revenues derived from O&P providers, the VA and rehabilitation hospitals, the Company recognizes revenue when control passes to the customer in an amount that reflects the consideration the Company expects to receive in exchange for those services. Revenues may be recognized upon shipment or upon delivery, depending on the terms of the arrangement, provided that persuasive evidence of an arrangement exists, there are no uncertainties regarding customer acceptance and collectability is deemed probable. In certain cases, the Company ships its products to O&P providers pending reimbursement from non-government, third party payers. As a result of this arrangement, elements of the revenue recognition criteria have not been met upon shipment. In this instance, the Company recognizes revenue when the amount is estimable and the Company determines it is probable that payment will be received. In many cases, the Company is not able to recognize revenue in these situations until payment is received, as then all of the revenue recognition criteria have been met. The Company has elected to record taxes collected from customers on a net basis and does not include tax amounts in revenue or cost of revenue. License Revenue If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when the license is transferred to the customer, the customer is able to use and benefit from the license, and collectability is deemed probable. On January 21, 2021, we entered into a definitive agreement with Beijing Ryzur Medical Investment Co., Ltd. (“Ryzur Medical”), a medical device manufacturer based in Beijing, to form a joint venture (the “JV”) to manufacture and sell our current and future products in greater China, including Hong Kong, Macau and Taiwan (the “JV Agreement”). Under the Agreements, we are entitled to receive an upfront license fee of $ 2.7 million, of which $ 1.0 million has been paid and recognized as revenue as of June 30, 2022. The company will recognize revenue on the remaining amount due upon payment as the fee has not been paid according the to the contractual terms. Contract Balances The timing of revenue recognition may differ from the timing of payment by customers. The Company records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. The Company had approximately $ 3,100 and $ 1,500 of deferred revenue as of June 30, 2022 and December 31, 2021, respectively. Disaggregated Revenue from Contracts with Customers The following table presents revenue by major source: For the Three Months For the Six Months 2022 2021 2022 2021 Direct to patient $ 3,056,588 $ 2,300,129 $ 4,908,732 $ 4,027,059 Clinical/Medical providers 620,987 804,165 $ 1,636,769 $ 1,413,724 License revenue - - 1,000,000 - Total revenue from contracts with customer $ 3,677,575 $ 3,104,294 $ 7,545,501 $ 5,440,783 Geographic Data The Company generated 91 % of its total and product revenue from the United States, 9 % from Germany, and an immaterial amount from other international locations for the three months ended June 30, 2022. The Company generated 90 % of its product and total revenue from the United States, 10 % from Germany, and immaterial amounts from international locations for the three months ended June 30, 2021. During the six months ended June 30, 2022, the Company generated 74 % of its total revenues from the United States, 12 % from Germany, 13 % from China and 1 % from other international locations. Excluding license revenue during the six months ended June 30, 2022, the Company generated 85 % of its product revenues from the United States, 14 % from Germany and 1 % from other international locations. During the six months ended June 30, 2021, the Company generated 89 % of its total and product revenues from the United States, 11 % from Germany, and immaterial amounts from other international locations Cost of Revenue In conjunction with the adoption of ASC 606, there are certain cases in which the Company will expense costs when incurred as required by ASC 340-40-25. In certain cases, the Company ships the MyoPro device to O&P providers, or provides the device directly to patients, pending reimbursement from third-party payers, after which revenue is recognized. For the three and six months ended June 30, 2022 , the Company recorded cost of goods sold of approximately $ 254,900 and $ 395,400 , resp ectively without corresponding revenue, respectively. For the three and six months ended June 30, 2021, the Company recorded cost of goods sold of $ 69,900 and $ 94,700 witho ut corresponding revenue, respectively. Direct billing fees paid to O&P providers for services they provide in conjunction with patient evaluations are expensed as incurred as required by ASC 340-40-25, as a cost of obtaining a contract. These costs are recorded as sales and marketing expense. Internal costs incurred and fees paid to O&P providers to measure, fit and deliver the device to patients are expensed to cost of revenue.
Advertising	Advertising The Company charges the costs of advertising to operating expenses as incurred. Advertising expense amounted to approximately $ 1,036,200 and $ 766,500 during the three months ended June 30, 2022 and 2021 , respectively and approximately $ 1,989,600 and $ 1,609,100 during the six months ended June 30, 2022 and 2021 , respectively.
Foreign Currency Translation	Foreign Currency Translation The functional currency of the Company’s foreign subsidiary, Myomo Europe GmbH, is the Euro. Net foreign currency gains and losses during the three and six months ended June 30, 2022 were immaterial and included in accumulated other comprehensive loss in the condensed consolidated balance sheet. Transaction foreign exchange gains and losses are included in net loss. Foreign exchange translation gains and losses from the functional currency of Myomo Europe GmbH, which is the Euro, to U.S. dollars are captured in other comprehensive loss. The balance sheet is translated using the spot rate on the day of reporting and the income statement is translated monthly using the average rate for the month.
Net Loss per Share	Net Loss per Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding, plus potentially dilutive common shares. Restricted stock, restricted stock units, stock options and warrants are excluded from the diluted net loss per share calculation when their impact is antidilutive. The Company reported a net loss for the three and six months ended June 30, 2022 and 2021, and as a result, all potentially dilutive common shares are considered antidilutive for these periods. Potential common shares issuable consist of the following at: June 30, 2022 2021 Stock options 31,390 29,326 Restricted stock units 513,631 299,484 Restricted stock - 10 Warrants 691,554 1,709,441 Total 1,236,575 2,038,261
Recent Accounting Standards	Recent Accounting Standards In May 2021, the FASB issued ASU 2021-04 Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early application is permitted, including in an interim period as of the beginning of the fiscal year that includes that interim period. We adopted the provisions of ASU 2021-04 in the fourth quarter of 2021. The implementation resulted in a deemed dividend of approximately $ 640,000 on the discounting and repricing of certain warrants.
Subsequent Events	Subsequent Events The Company evaluates whether there have been subsequent events through the date the financial statements were issued and determines whether subsequent events exist that would require recognition in the financial statements or disclosure in the notes to the financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Revenue by Major Source	The following table presents revenue by major source: For the Three Months For the Six Months 2022 2021 2022 2021 Direct to patient $ 3,056,588 $ 2,300,129 $ 4,908,732 $ 4,027,059 Clinical/Medical providers 620,987 804,165 $ 1,636,769 $ 1,413,724 License revenue - - 1,000,000 - Total revenue from contracts with customer $ 3,677,575 $ 3,104,294 $ 7,545,501 $ 5,440,783
Summary of Potential Common Shares Issuable	Potential common shares issuable consist of the following at: June 30, 2022 2021 Stock options 31,390 29,326 Restricted stock units 513,631 299,484 Restricted stock - 10 Warrants 691,554 1,709,441 Total 1,236,575 2,038,261

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following at: June 30, December 31, Finished goods $ 453,840 $ 176,082 Work in process 18,684 23,161 Rental units 62,531 62,531 Parts and subassemblies 772,457 584,996 1,307,512 846,770 Less: reserve for rental units ( 46,576 ) ( 38,462 ) Inventories, net $ 1,260,936 $ 808,308

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Cash Equivalents Measured at Fair Value on Recurring Basis	Cash equivalents measured at fair value on a recurring basis at June 30, 2022 were as follows: In Active Significant Significant Total Cash equivalents $ 9,205,167 $ — $ — $ 9,205,167 Cash equivalents measured at fair value on a recurring basis at December 31, 2021 were as follows: In Active Markets for Identical Assets or Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Cash equivalents $ 14,803,456 $ — $ — $ 14,803,456

Accounts Payable and other Ac_2

Accounts Payable and other Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Summary of Accounts Payable and Other Accrued Expenses	Accounts Payable and Other Accrued Expenses consists of the following at: June 30, December 31, Trade payables $ 859,536 $ 723,352 Accrued compensation and benefits 1,115,643 2,188,869 Accrued professional services 110,706 108,417 Deferred payroll taxes under CARES Act 113,423 113,423 Warranty reserve 200,465 176,281 Customer Deposits 659,059 192,501 Other 386,507 446,941 $ 3,445,339 $ 3,949,784

Stock Award Plans and Stock-b_2

Stock Award Plans and Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Grant Date Fair Value	The assumptions underlying the calculation of grant date fair value per share for the six months ended June 30, 2022 are as follows: For the Six Months 2022 Number of options granted 1,700 Weighted-average expected volatility 117.18 % Weighted-average risk-free interest rate 1.68 % Weighted-average expected option term 6.25 Weighted-average dividend yield — % Weighted-average fair value per share $ 6.92
Schedule of Stock-based Compensation Expense	The Company recognized stock-based compensation expense related to the issuance of stock option awards, restricted stock awards and restricted stock units to employees, non-employees and directors in the statements of operations as follows: Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Cost of goods sold $ 23,184 $ 12,831 $ 24,354 $ 21,864 Research and development 29,573 24,707 76,107 72,110 Selling, general and administrative 292,466 325,774 511,032 435,309 Total $ 345,223 $ 363,312 $ 611,493 $ 529,283

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Summary of Maturity of Operating Lease Liabilities	The amount and the maturity of the Company’s operating lease liabilities as of June 30, 2022, are as follows: June 30, 2022 2022 (June 30 - December 31) $ 275,625 2023 411,142 2034 159,872 2025 67,981 2026 — Thereafter — Total future minimum lease payments 914,620 Less imputed interest 149,197 Total operating lease liabilities $ 765,423 Included in the condensed consolidated balance sheet: Current operating lease liabilities $ 436,694 Non-current operating lease liabilities 328,729 Total operating lease liabilities $ 765,423
Summary of Operating Lease Cost	For the three and six months ended June 30, 2022 and 2021, the total lease cost is comprised of the following amounts: For the Three Months For the Six Months 2022 2021 2022 2021 Operating lease expense 125,293 102,963 241,904 170,472 Short-term lease expense 1,300 2,175 3,250 25,859 Total lease expense $ 126,593 $ 105,138 $ 245,154 $ 196,331
Summary of Additional Information Related to Operating Leases	The following summarizes additional information related to operating leases: June 30, 2022 Weighted-average remaining lease term (in years) 2.1 Weighted-average discount rate 20 %

Description of Business - Addit

Description of Business - Additional Information (Detail) - USD ($)		1 Months Ended	3 Months Ended				6 Months Ended
	Aug. 01, 2022	Jul. 31, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Net loss			$ 2,908,922	$ 2,814,934	$ 2,621,315	$ 2,960,794	$ 5,723,856	$ 5,582,109
Cash used in operating activities							4,970,597	$ 5,509,514
Accumulated deficit			83,786,078				83,786,078		$ 78,062,222
Shares value			698				698		$ 687
Cash balance			$ 10,200,000				$ 10,200,000
Common Stock Purchase Agreement [Member] | Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares value	$ 2,300,000
Minimum | Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares value	$ 2,300,000
Minimum | Keystone Capital Partners [Member] | Common Stock Purchase Agreement [Member] | Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Committed to purchase	1,399,348	1,399,348
Maximum | Keystone Capital Partners [Member] | Common Stock Purchase Agreement [Member] | Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares value	$ 5,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)			3 Months Ended		6 Months Ended
	Mar. 28, 2022	Jan. 21, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Summary Of Significant Accounting Policies [Line Items]
Reclassifications out of accumulated other comprehensive loss					$ 0	$ 0
Loss on investment in minority interest			$ 33,208		33,208
Allowance for doubtful accounts			26,000		26,000		$ 0
Cash consideration paid					$ 199,000	$ 0
Impairment charge			$ 0
Percentage of direct billing channel revenue insures represent			34%	40%	41%	28%
Revenue			$ 3,677,575	$ 3,104,294	$ 7,545,501	$ 5,440,783
Deferred revenue			3,100		3,100		$ 1,500
Cost of goods sold						112,900
Advertising expense			1,036,200	766,500	1,989,600	1,609,100
Deemed dividend on discounting of warrants					640,000
Accounting Standards Update 2014-09
Summary Of Significant Accounting Policies [Line Items]
Cost of goods sold			$ 254,900	$ 69,900	$ 395,400	$ 94,700
Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] | United States [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of revenue					74%
Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] | China [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of revenue					13%
Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] | Germany [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of revenue					12%
Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] | Other International Locations [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of revenue					1%
Product Revenue [Member] | Geographic Concentration Risk [Member] | United States [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of revenue			91%	90%	85%	89%
Product Revenue [Member] | Geographic Concentration Risk [Member] | Germany [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of revenue			9%	10%	14%	11%
Product Revenue [Member] | Geographic Concentration Risk [Member] | Other International Locations [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of revenue					1%
Beijing Ryzur Medical Investment Co., Ltd
Summary Of Significant Accounting Policies [Line Items]
Upfront license fee		$ 2,700,000
License Revenue
Summary Of Significant Accounting Policies [Line Items]
Revenue			$ 0		$ 1,000,000
License Revenue | Beijing Ryzur Medical Investment Co., Ltd
Summary Of Significant Accounting Policies [Line Items]
Revenue					1,000,000
O&P Providers or Third Party Payors [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue recognized			$ 1,651,900	$ 397,100	$ 1,284,200	$ 1,489,700
Jiangxi Myomo Medical Assistive Appliance Co. Ltd
Summary Of Significant Accounting Policies [Line Items]
Ownership percentage	19.90%
Cash consideration paid	$ 199,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Revenue by Major Source (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation Of Revenue [Line Items]
Total revenue from contracts with customer	$ 3,677,575	$ 3,104,294	$ 7,545,501	$ 5,440,783
Direct to Patient [Member]
Disaggregation Of Revenue [Line Items]
Total revenue from contracts with customer	3,056,588	2,300,129	4,908,732	4,027,059
Clinical/Medical Providers [Member]
Disaggregation Of Revenue [Line Items]
Total revenue from contracts with customer	620,987	$ 804,165	1,636,769	$ 1,413,724
License Revenue [Member]
Disaggregation Of Revenue [Line Items]
Total revenue from contracts with customer	$ 0		$ 1,000,000

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Potential Common Shares Issuable (Detail) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,236,575	2,038,261
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	31,390	29,326
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	513,631	299,484
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	0	10
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	691,554	1,709,441

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Finished goods	$ 453,840	$ 176,082
Work in process	18,684	23,161
Rental units	62,531	62,531
Parts and subassemblies	772,457	584,996
Total cost	1,307,512	846,770
Less: reserve for rental units	(46,576)	(38,462)
Inventories, net	$ 1,260,936	$ 808,308

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Cash Equivalents Measured at Fair Value on Recurring Basis (Detail) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	$ 9,205,167	$ 14,803,456
In Active Markets for Identical Assets or Liabilities (Level 1) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	$ 9,205,167	$ 14,803,456

Accounts Payable and Other Ac_3

Accounts Payable and Other Accrued expenses - Summary of Accounts Payable and Other Accrued Expenses (Detail) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Trade payables	$ 859,536	$ 723,352
Accrued compensation and benefits	1,115,643	2,188,869
Accrued professional services	110,706	108,417
Deferred payroll taxes under CARES Act	113,423	113,423
Warranty reserve	200,465	176,281
Customer Deposits	659,059	192,501
Other	386,507	446,941
Total	$ 3,445,339	$ 3,949,784

Common Stock and Warrants - Add

Common Stock and Warrants - Additional Information (Detail)			3 Months Ended		6 Months Ended
	Jun. 25, 2021 USD ($) Rate	Feb. 13, 2020 Customer $ / shares shares	Jun. 30, 2022 shares	Jun. 30, 2021 shares	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 USD ($) shares
Class of Stock [Line Items]
Proceeds from exercise of warrants | $					$ 0	$ 7,288,275
Restricted Stock [Member]
Class of Stock [Line Items]
Number of shares, Vested			0	10	0	20
ATM Facility [Member]
Class of Stock [Line Items]
Number of shares offer and sell | $	$ 300,000
Percentage of gross proceeds from sales of common stock | Rate	3%
Proceeds from issuance of common stock | $	$ 15,000,000
Stock issued during period			0		0
Investor Warrants [Member]
Class of Stock [Line Items]
Warrants exercised					0	826,700
Proceeds from exercise of warrants | $						$ 7,288,300
Underwriter Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase common stock		230,373
Common stock warrants, exercise price per share | $ / shares		$ 7
Warrants maturity date		Feb. 13, 2025
Warrants exercised						162,575
February 2020 Offering [Member]
Class of Stock [Line Items]
Number of shares entitled to warrant holder | Customer		1
February 2020 Offering [Member] | Investor Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase common stock		2,143,000
Common stock warrants, exercise price per share | $ / shares		$ 7.50
Warrants maturity date		Feb. 13, 2025

Stock Award Plans and Stock-b_3

Stock Award Plans and Stock-based Compensation - Additional Information (Detail) - USD ($)		3 Months Ended		6 Months Ended
	Jan. 01, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Income tax benefit recognized		$ 0	$ 0	$ 0	$ 0
Number of stock options granted				1,700
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost		93,700		$ 93,700
Weighted-average remaining contractual term				2 years 6 months 29 days
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost		$ 2,057,300		$ 2,057,300
Weighted-average remaining contractual term				1 year 10 months 24 days
2018 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for future grant		38,209		38,209
Number of common shares reserved for issuance	274,789
Percentage increase in number of shares of common stock reserved and available for issuance	4%

Stock Award Plans and Stock-b_4

Stock Award Plans and Stock-based Compensation - Schedule of Grant Date Fair Value (Detail)	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Number of options granted | shares	1,700
Weighted-average expected volatility	117.18%
Weighted-average risk-free interest rate	1.68%
Weighted-average expected option term (in years)	6 years 3 months
Weighted-average dividend yield	0%
Weighted-average fair value per share of grants | $ / shares	$ 6.92

Stock Award Plans and Stock-b_5

Stock Award Plans and Stock-based Compensation - Schedule of Stock-based Compensation Expense (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share based compensation expense	$ 345,223	$ 363,312	$ 611,493	$ 529,283
Cost of Goods Sold [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share based compensation expense	23,184	12,831	24,354	21,864
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share based compensation expense	29,573	24,707	76,107	72,110
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share based compensation expense	$ 292,466	$ 325,774	$ 511,032	$ 435,309

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2021 USD ($)
Related Party Transactions [Abstract]
Revenue recognized from related party	$ 25,900
Cost of goods sold	$ 112,900

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) Customer	Jun. 30, 2021 Customer	Jun. 30, 2022 USD ($) Customer	Jun. 30, 2021 Customer	Dec. 31, 2021 USD ($)
Commitments And Contingencies [Line Items]
Description of operating lease agreement for office space			The Company has a non-cancelable sublease agreement for its corporate headquarters in Boston, MA expiring in 2023, and it has a non-cancelable lease agreement for its manufacturing space in Boston and office space in Fort Worth, TX both expiring in 2025 with early termination available at the company’s discretion in 2023. Termination options were not included in the lease term for the Company’s existing operating leases. Certain arrangements have discounted rent periods or escalating rent payment provisions. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheets. We recognize rent expense on a straight-line basis over the lease term.
Operating lease assets with right of use | $	$ 695,933		$ 695,933		$ 632,906
Sales Revenue, Net [Member]
Commitments And Contingencies [Line Items]
Number of customers	0	0	0	0
Accounts Receivable [Member]
Commitments And Contingencies [Line Items]
Number of customers			1	1
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | One U.S. Insurance Payer [Member]
Commitments And Contingencies [Line Items]
Percentage of revenue	28%	30%	31%	28%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Patients with Medicare Advantage Insurance Plans [Member]
Commitments And Contingencies [Line Items]
Percentage of revenue	71%	52%	63%	54%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Insurer [Member]
Commitments And Contingencies [Line Items]
Percentage of revenue			68%	68%

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Maturity of Operating Lease Liabilities (Detail) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Lessee, Operating Lease, Liability, to be Paid [Abstract]
2022 (March 31 - December 31)	$ 275,625
2023	411,142
2034	159,872
2025	67,981
Total future minimum lease payments	914,620
Less imputed interest	149,197
Total operating lease liabilities	765,423
Included in the condensed consolidated balance sheet:
Current operating lease liability	436,694	$ 333,380
Non-current operating lease liability	328,729	$ 401,622
Total operating lease liabilities	$ 765,423

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Operating Lease Cost (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Lease, Cost [Abstract]
Operating lease expense	$ 125,293	$ 102,963	$ 241,904	$ 170,472
Short-term lease expense	1,300	2,175	3,250	25,859
Total lease expense	$ 126,593	$ 105,138	$ 245,154	$ 196,331

Commitments and Contingencies_4

Commitments and Contingencies - Summary of Additional Information Related to Operating Leases (Detail)	Jun. 30, 2022
Leases [Abstract]
Weighted-average remaining lease term (in years)	2 years 1 month 6 days
Weighted-average discount rate	20%

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)		1 Months Ended
	Aug. 01, 2022	Jul. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Shares value			$ 698	$ 687
Subsequent Event [Member] | Keystone [Member]
Subsequent Event [Line Items]
Beneficial ownership limitation		4.99%
Subsequent Event [Member] | Common Stock Purchase Agreement [Member]
Subsequent Event [Line Items]
Shares value	$ 2,300,000
Subsequent Event [Member] | Common Stock Purchase Agreement [Member] | Keystone [Member]
Subsequent Event [Line Items]
Percentage increase in number of shares of common stock reserved and available for issuance	10%	10%
Share issued		50,000
Percentage of outstanding shares purchased		19.99%
Expenses incurred in conjunction with the transaction		$ 20,000
Subsequent Event [Member] | Maximum | Common Stock Purchase Agreement [Member] | Keystone [Member]
Subsequent Event [Line Items]
Aggregate size of facility maximum amount		$ 5,000,000
Shares value	$ 5,000,000
Subsequent Event [Member] | Minimum
Subsequent Event [Line Items]
Shares value	$ 2,300,000
Subsequent Event [Member] | Minimum | Keystone [Member]
Subsequent Event [Line Items]
Price per share		$ 0.50
Subsequent Event [Member] | Minimum | Common Stock Purchase Agreement [Member] | Keystone [Member]
Subsequent Event [Line Items]
Committed to purchase	1,399,348	1,399,348